ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > For those that Sold at 0.26 CAD Today

<< Previous

Bullboard Posts

Next >>

Comment by Gbathaton Aug 13, 2021 7:52pm

188 Views

Post# 33705248

RE:RE:RE:RE:RE:RE:RE:For those that Sold at 0.26 CAD Today

This wasn't due to your prediction. I cut my position by half today. I am annoyed by the ever moving goal posts for phase 1.

I still have plenty of shares if they do by some chance announce Phase 1 funding, some other deal, or covid antibody sales. But the other half of my investment is going elsewhere for a while.

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks